**MHRA**
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

**gov.uk/mhra**

# Decision Cover Letter

## Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan and to the deferral

MHRA-100303-PIP01-21-M01

# Scope of the Application

## Active Substance(s)

DARUNAVIR; COBICISTAT; EMTRICITABINE; TENOFOVIR ALAFENAMIDE

## Condition(s)

Treatment of human immunodeficiency virus type-1 (HIV-1) infection

## Pharmaceutical Form(s)

Film-coated tablet

## Route(s) of Administration

Oral use

## Name / Corporate name of the PIP applicant

Janssen-Cilag Limited

## Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Janssen-Cilag Limited submitted to the licensing authority on 26/11/2021 10:17 GMT an application for a Modification

The procedure started on 19/05/2022 15:00 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

**MHRA**
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

**gov.uk/mhra**

# Final Decision Letter

MHRA-100303-PIP01-21-M01

Of 16/06/2022 15:32 BST

On the adopted decision for DARUNAVIR; COBICISTAT; EMTRICITABINE; TENOFOVIR ALAFENAMIDE (MHRA-100303-PIP01-21-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for DARUNAVIR; COBICISTAT; EMTRICITABINE; TENOFOVIR ALAFENAMIDE, Film-coated tablet , Oral use .

This decision is addressed to Janssen-Cilag Limited, 50-100 Holmers Farm Way, High Wycombe, United Kingdom, HP12 4EG

# ANNEX I

## 1. Waiver

### 1.1 Condition:

| |
|---|
| Treatment of human immunodeficiency virus type-1 (HIV-1) infection The waiver applies / applied to: Paediatric Subset(s): The paediatric population below 6 years of age or weighing less than 25 kg Pharmaceutical form(s): Film-coated tablet Route(s) of administration: Oral use Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments |

## 2. Paediatric Investigation Plan:

### 2.1 Condition(s):

| |
|---|
| Treatment of human immunodeficiency virus type-1 (HIV-1) infection |

## 2.2 Indication(s) targeted by the PIP:

Treatment of HIV-1 infection in paediatric subjects weighing 25 kg or more from 6 years of age

## 2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population weighing 25 kg or more from 6 years of age

## 2.4 Pharmaceutical Form(s):

Film-coated tablet

## 2.5 Studies:

| Study Type | Number of Studies | Study Description |
|---|---|---|
| **Quality Measures** | 1 | Study 1 Evaluation of the acceptability for paediatric patients between 12 to less than 18 year olds of the adult tablet of Symtuza. Study 2 Development of a scored film-coated tablet of Symtuza and evaluation of acceptability for patients aged at least 6 years old weighing at least 25 kg. |
| **Non-Clinical Studies** | 0 | Not applicable |
| **Clinical Studies** | 1 | Study 3 Study deleted during procedure EMEA-001825-PIP01-15-M02 Study 4 This study is included as Study 3 (GS-US-311-1269) in procedure EMEA-001577-PIP02-14 (P/0032/2015 of 16 February 2015) and subsequent modifications thereof. Open-label, uncontrolled trial to evaluate pharmacokinetics (PK), safety, tolerability and efficacy of emtricitabine/ tenofovir alafenamide (F/TAF) fixed-dose combination (FDC) in children from 6 to less than 18 years of age with HIV-1 infection, who are virologically suppressed on an antiretroviral (ARV) regimen or treatment naïve (GS-US-311-1269). |
| **Extrapolation, Modeling & Simulation Studies** | 1 | Study 5 Modelling and simulation study for cobicistat-boosted darunavir (D) doses in paediatric subjects 25 kg to less than 40 kg. |
| **Other Studies** | 0 | Not applicable |
| **Other Measures** | 0 | Not applicable |

## 3. Follow-up, completion and deferral of a PIP:

| | |
|---|---|
| **Concerns on potential long term safety and efficacy issues in relation to paediatric use:** | Yes |
| **Date of completion of the paediatric investigation plan:** | 30/06/2021 |
| **Deferral of one or more studies contained in the paediatric investigation plan:** | Yes |